Tiakis Biotech is preparing for a Phase 2 U.S. trial of tiprelestat for PAH after completing a data package required for ...

This holiday season, columnist Anna Jeter is searching for some silver linings in her life and to try to be grateful, despite ...

A mouse study shows overproduction of the naturally occurring hormone adrenomedullin reduced lung injury and PH in ...

Merck Canada said it has successfully completed negotiations on its PAH therapy Winrevair with the pan‑Canadian ...

Scientists identified two proteins as biomarkers of CTEPH severity and progression, a discovery that could pave the way for ...

Pulmonary hypertension (PH) is a rare but life-threatening disease that affects the pulmonary arteries, making them narrow and thick. The vessels, which are responsible for transporting blood from the ...

The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research.

What is Veletri for pulmonary arterial hypertension? Veletri (epoprostenol) is an intravenous (into-the-vein) infusion therapy approved to improve exercise capacity in people with pulmonary arterial ...

Merck plans a Phase 3 trial of Winrevair after a Phase 2 study testing it in CpcPH due to HFpEF hit its main goal.

Low oxygen levels, or hypoxia, in early life impaired lung blood vessel growth, leading to severe pulmonary hypertension in a mouse model.

Although there is no cure yet for pulmonary hypertension (PH), there are a variety of therapies available that can help manage the symptoms of the disease and maintain or improve the quality of life ...

Pulmonary hypertension (PH) is a rare but severe health condition characterized by high blood pressure in the pulmonary arteries. It is diagnosed when the arteries that transport blood from the heart ...